| Angela Park, DO | |
|
575 N River St, Wilkes Barre, PA 18764-2613 | |
| (570) 552-4450 | |
| Not Available |
| Full Name | Angela Park |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Location | 575 N River St, Wilkes Barre, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063073096 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | R-11683 (Iowa) | Secondary |
| 207R00000X | Internal Medicine | OS023299 (Pennsylvania) | Primary |
| Entity Name | Naz Hospitalists Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437137072 PECOS PAC ID: 5294627816 Enrollment ID: O20040329000289 |
News Archive
Many patients with advanced cancer suffer from cachexia, a condition also called body-wasting or wasting syndrome, which causes significant weight loss, extreme fatigue and reduces quality of life.
After testing about 5,600 existing medications for their effectiveness against drug-resistant strains of tuberculosis (TB), researchers from Weill Cornell Medical College reported this week in the Proceedings of the National Academy of Sciences that oxyphenbutazone, "an anti-inflammatory medication marketed in the 1950s as Tandearil and still used in veterinary medicine," killed both latent and active TB bacteria in test-tube experiments, the Los Angeles Times' "Booster Shots" blog reports.
Roswell Park Cancer Institute (RPCI) is one of 27 North American research institutions that have been selected to be part of the Cancer Immunotherapy Trials Network (CITN), a new immunotherapy initiative funded by the National Cancer Institute (NCI). Kunle Odunsi, MD, PhD, FRCOG, FACOG, Director of the Center for Immunotherapy and Chair of Gynecologic Oncology at RPCI, will serve as Principal Investigator of the Institute's role in this collaborative investigative effort.
Cancer therapies targeting specific molecular subtypes of the disease allow physicians to tailor treatment to a patient's individual molecular profile. But scientists are finding that in many types of cancer the molecular subtypes are more varied than previously thought and contain further genetic alterations that can affect a patient's response to therapy.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Angela Park, DO Po Box 1475, Des Moines, IA 50305-1475 Ph: (515) 643-2261 | Angela Park, DO 575 N River St, Wilkes Barre, PA 18764-2613 Ph: (570) 552-4450 |
News Archive
Many patients with advanced cancer suffer from cachexia, a condition also called body-wasting or wasting syndrome, which causes significant weight loss, extreme fatigue and reduces quality of life.
After testing about 5,600 existing medications for their effectiveness against drug-resistant strains of tuberculosis (TB), researchers from Weill Cornell Medical College reported this week in the Proceedings of the National Academy of Sciences that oxyphenbutazone, "an anti-inflammatory medication marketed in the 1950s as Tandearil and still used in veterinary medicine," killed both latent and active TB bacteria in test-tube experiments, the Los Angeles Times' "Booster Shots" blog reports.
Roswell Park Cancer Institute (RPCI) is one of 27 North American research institutions that have been selected to be part of the Cancer Immunotherapy Trials Network (CITN), a new immunotherapy initiative funded by the National Cancer Institute (NCI). Kunle Odunsi, MD, PhD, FRCOG, FACOG, Director of the Center for Immunotherapy and Chair of Gynecologic Oncology at RPCI, will serve as Principal Investigator of the Institute's role in this collaborative investigative effort.
Cancer therapies targeting specific molecular subtypes of the disease allow physicians to tailor treatment to a patient's individual molecular profile. But scientists are finding that in many types of cancer the molecular subtypes are more varied than previously thought and contain further genetic alterations that can affect a patient's response to therapy.
› Verified 8 days ago
Dr. Paul Anthony Arkless, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 E Mountain Dr, Pulmonary Department, Wilkes Barre, PA 18711 Phone: 570-808-5770 | |
Dr. Lida Eatedali, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1111 East End Blvd, Vamc., Wilkes Barre, PA 18711 Phone: 570-824-3521 | |
Dr. Sanjaykumar Doshi, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: Va Medical Center, 1111 East End Blvd, Wilkes Barre, PA 18702 Phone: 570-824-3521 | |
Dr. Smita S. Nikam, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1000 E Mountain Blvd, Wilkes Barre, PA 18711 Phone: 570-820-6114 Fax: 570-826-7698 | |
Carol L Myers, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 E Mountain Blvd, Wilkes Barre, PA 18711 Phone: 570-808-6444 Fax: 570-808-5040 | |
Patrick Michael Aquilina, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 545 N River St Ste 240, Wilkes Barre, PA 18702 Phone: 570-819-2825 Fax: 570-819-1445 | |
Dr. Richard Abbas Alley, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 166 Hanover St, 203, Wilkes Barre, PA 18702 Phone: 570-825-8780 Fax: 570-825-8785 |